PubMed · 2010 · 10 citations · 26 references
MedicineMolecular BiologyPharmacologyEpigeneticsGene ExpressionTranscriptional RegulationGene Expression RegulationPromoter RegulationTranscriptional ControlClofarabine-based TherapyDna Methylation ModulationEpigenetic RegulationEpigenetic Silencing Of Tumor Suppressor GenesP21 RegulationPromoter MethylationPromoter Methylation AnalysisPromoters
BACKGROUND: In this study, the effect of clofarabine, a new generation 2'-deoxyadenosine analogue, on promoter methylation and transcriptional activity of selected genes (PTEN, APC, RARB2, ZAP70) in K562 cells was assessed. MATERIALS AND METHODS: Promoter methylation was estimated using methylation-sensitive restriction analysis. The mRNA level of the genes was measured with real-time PCR. RESULTS: The inhibitory cytostatic index (IG(50)) for clofarabine in K562 cells cultured for 72 (or 96) h was 8 nM. The drug (20 nM) caused: (i) potent diminution in methylation of PTEN promoter, moderate methylation reduction of APC and RARB2 promoters, and complete methylation of ZAP70 promoter; (ii) significant stimulation of PTEN, APC, RARB, and p21 mRNA expression and (iii) decline in mRNA level of ZAP70 and DNMT1 genes. CONCLUSION: The results indicated that clofarabine is involved in epigenetic regulation of transcriptional activity of the tested tumour suppressor genes and genes encoding proteins involved in DNA methylation process.
26
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia
Jenny Orchard, Rachel Ibbotson, Zadie Davis et al. · The Lancet · 2004 · 558 citations
Medicine, Hematology, Immunology +12
Aberrant methylation during cervical carcinogenesis.
A K Virmani, Carolyn Y. Muller, Aditi Rathi et al. · PubMed · 2001 · 201 citations
Hagop M. Kantarjian, Harry P. Erba, David F. Claxton et al. · Journal of Clinical Oncology · 2009 · 193 citations · Full text
Pharmacy, Oncology, Pharmacotherapy +13